[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-graft\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-graft":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100649287","phase-4-pelashield-vs-xeroform-100649287",false,"NCT07734519","Pelashield vs Xeroform","A Prospective Randomized Split-Site Study of Donor-Site Pain and Appearance Following Pelashield TM Versus Xeroform","Inclusion Criteria:\n\n* Undergoing split-thickness skin graft harvest, with a donor site sufficiently large to allow division into two comparable halves for randomized dressing application.\n* Donor site located in an area amenable to standardized photography and serial appearance assessment.\n* Ability to provide informed consent.\n* Willingness and ability to participate in scheduled follow-up visits for donor-site assessment, including standardized photography.\n* Donor-site management expected to follow the standardized study dressing protocol for the duration of the early healing period.\n\nExclusion Criteria:\n\n* Inability, or anticipated inability, to reliably report pain within 1hour (or in recovery room) after surgery\n* Known allergy or hypersensitivity to lidocaine, silver-containing dressings, or other components of the study dressings.\n* Donor sites that are too small, irregularly shaped, or anatomically unsuitable to allow division into two comparable treatment halves.\n* Pre-existing skin disease at or adjacent to the donor-site region that may affect wound healing or scar appearance\n* Clinical situations in which the treating surgeon anticipates that protocol-based donor-site care cannot be maintained, including cases requiring non-standard dressings or adjunctive local therapies.\n* Anticipated inability to complete follow-up assessments, including inability to obtain evaluable standardized photographs at key time points.\n* Severe uncontrolled systemic conditions likely to significantly impair wound healing, at the discretion of the investigator (e.g., severe immunosuppression or other conditions making reliable donor-site healing unlikely).\n* Allergy to any local anesthetic\n* Allergy or sensitivity to silver\n* Pregnancy","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this research study is to compare the effects (good or bad) of a new skin graft dressing (PelashieldTM) compared to the one traditionally used (Xeroform).",[26],"Skin Graft",[28,29,30],"Pelashield","Xeroform","donor site pain","NOT_YET_RECRUITING","2026-07-29",{"date":34,"type":35},"2026-07-31","ACTUAL",{"date":37,"type":20},"2026-08",{"date":39,"type":20},"2027-07",{"name":41,"class":42},"Wake Forest University Health Sciences","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100485404","multi-center-observation-of-sentinel-skin-graft-for-detecting-acute-rejection-after-renal-transplantation-100485404","NCT05600634","Multi Center Observation of Sentinel Skin Graft for Detecting Acute Rejection After Renal Transplantation","Multi Center Clinical Observation of Sentinel Skin Graft From the Same Donor Source for Detecting Acute Rejection After Renal Transplantation","Inclusion Criteria:\n\n1. Patients with end-stage renal disease undergoing renal transplantation;\n2. 18-60 years old;\n3. Postoperative follow-up points are complete (visit the hospital every week in the first month after surgery, every two weeks in 2-3 months, every four to six months, and every three months in 7-12 months. Follow up at any time when skin rejection is observed. The follow-up time may be adjusted when the condition changes);\n4. The participants had good compliance, volunteered to participate in the test and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Untreated or disseminated malignant tumor;\n2. Active period of infectious diseases;\n3. Serious cardiovascular disease occurred recently;\n4. Combined with other important organ failure;\n5. History of mental illness or cognitive impairment;","60 Years",{"count":53,"type":20},24,"OBSERVATIONAL","The purpose of this study was to explore the accuracy of sentinel skin grafts from the same donor source in diagnosing renal allograft rejection, and to provide new ideas and options for the later clinical diagnosis of renal allograft rejection. Further, try to provide timing guidance for early immunization intervention.",[57,26],"Kidney Transplant Rejection","RECRUITING","2023-11-27",{"date":61,"type":35},"2023-11-28",{"date":63,"type":20},"2024-01-01",{"date":65,"type":20},"2026-12-31",{"name":67,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University",3]